Ann: CardioCel receives market approval in UAE, page-3

ASX ANNOUNCEMENT
CARDIOCEL® RECEIVES MARKET APPROVAL IN UAE
 Admedus and partner Genpharm receive marketing approval in UAE
 Initial orders for CardioCel® in UAE received
 Part of continued expansion in emerging markets
Brisbane, Australia 21st November, 2016
Admedus Limited (ASX: AHZ) today announced that, in collaboration with its regional
partner Genpharm, it has received market approval for CardioCel® in the United Arab
Emirates (UAE) and first orders. This follows on from the recent approval of the product
in Kuwait.
“As we continue to drive strong sales growth of CardioCel®, this approval is a significant
milestone in terms of our expansion of the product franchise across emerging markets.
The UAE is a strategically important location as a central hub in MENA for performing
cardiovascular surgery” stated Chair and Interim CEO, Mr Wayne Paterson.
CardioCel® is a single-ply bio-scaffold that remains functional, durable and free from
calcification. Engineered with Admedus’ proprietary ADAPT® technology, CardioCel®
provides superior restorative structural heart repair and reconstruction. Long-term
clinical studies using CardioCel® have shown no calcification eight years’ postimplantation.
CardioCel® is used in leading heart centers around the world for
cardiovascular repairs and reconstructions.
The UAE has over 500 cases of congenital defects per annum and an increasing number
of older patients with congenital defects seeking repair. The UAE is also an important
regional hub for cardiovascular surgery and healthcare in general.
“This is an important product approval for both cardiac surgeons and their patients in
the UAE and beyond. Bringing cutting edge medical products to the MENA region is one
of our primary goals and we are delighted, therefore, to announce the approval of
CardioCel® in the region” said Mr Karim Smaira, Managing Partner, Genpharm.
Admedus and Genpharm were well represented at the fifth scientific meeting for the
World Society of Paediatric and Congenital Heart Surgery (WSPCHS) held in Abu Dhabi
in October 2016.